PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 22, 2026ESC Heart Failure2 citationsOpen Access

Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study)

View Full Paper
PLP LeszekZCZoltan CsanádiIGI. Gruev

Key Points

  • This research aims to evaluate dapagliflozin's usage and treatment practices in heart failure patients.
  • Large non-interventional study
  • 1-year follow-up in Central Eastern Europe and the Baltic region
  • Assessment of guideline-directed medical therapy
  • High persistence rates of dapagliflozin observed
  • Low proportion of patients received complete guideline-directed medical therapy
  • Need for improved heart failure management decisions indicated

Abstract

This large non-interventional study provides a contemporary perspective of the treatments used in HFrEF over 1-year follow-up. Despite high dapagliflozin persistence rates, a low proportion of patients received complete guideline-directed medical therapy in optimal doses. Improvement of HF management decisions across the CEE-BA region is warranted.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Leszek et al. (2026) studied this question.

synapsesocial.com/papers/69bf3924c7b3c90b18b43685https://doi.org/10.1093/eschf/xvag085
Ask AI
Helpful
Bookmark
Share
View Full Paper